';
Please join RCPA for an afternoon of golf, which will benefit the RCPA PAC, on Wednesday, May 18, 2022, immediately following the RCPA Annual Membership Meeting. You can register here to attend the RCPA PAC golf fundraiser to be held at Dauphin Highlands Golf Course, Harrisburg, PA. Golf outing hole sponsorships are available to support this fundraiser, and we hope you will consider becoming a hole sponsor.
Not a golfer but would still like to support the RCPA PAC? For your convenience, you can now make a personal online contribution, which will provide financial support to state legislators or representatives who have demonstrated a strong, consistent, and positive interest in our legislative priorities. If you are interested in learning more about the RCPA PAC or donating, please visit our website, download the PAC FAQ Card and Donation Card, or email Jack Phillips, Director of Government Affairs.
On March 7, 2022, the Centers for Medicare and Medicaid Services (CMS) reissued the March 2022 preview reports for the inpatient rehabilitation facilities (IRFs). These reports are related to the Care Compare refresh to correct errors with two functional measures and the clostridium difficile infection outcome measure.

The Office of Inspector General (OIG) within the U.S. Department of Health and Human Services (HHS) has issued a favorable advisory opinion regarding contingency management (CM), an evidence-based approach for treating substance use disorders (SUD) that uses financial incentives to reward healthy behavior, such as abstinence and treatment retention, according to the National Council for Mental Wellbeing.
CM has been shown to be an effective approach for those with SUD in more than 100 randomized controlled trials over 50 years. Evidence shows it can double abstinence rates across opioids, stimulants, alcohol, tobacco, and nicotine, compared to usual care alone. It is the most effective and most evidence-based treatment for stimulant use disorders. In 2021, the Biden Administration declared advancing CM among its drug policy priorities.
The advisory opinion clears the way for CM for routine use in publicly funded substance use treatment programs and healthcare facilities under federal reimbursement, including Medicaid.